Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 2/20 | 0.42 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9565809 | 0.91 | THRB (0.50) | THRBTET2 | |
| SCHEMBL1791517 | 0.91 | THRB (0.50) | THRBTET2 | |
| SCHEMBL13142417 | 0.84 | TET2 (0.37) | THRBTET2MEN1ALDH1A1CYP1A2 | |
| SCHEMBL16285652 | 0.73 | THRB (0.41) | THRBMEN1ALDH1A1CYP1A2KMT2A | |
| SCHEMBL1000250 | 0.72 | TET2 (0.50) | THRBTET2MEN1ALDH1A1CYP1A2 | |
| SCHEMBL1000252 | 0.72 | TET2 (0.50) | THRBTET2MEN1ALDH1A1CYP1A2 | |
| SCHEMBL29098786 | 0.71 | THRB (0.50) | THRB | |
| SCHEMBL29098792 | 0.71 | THRB (0.50) | THRB | |
| SCHEMBL29098781 | 0.71 | THRB (0.50) | THRB | |
| SCHEMBL7269501 | 0.71 | THRB (0.50) | THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3446177-B1 | FLAME RETARDANCY OF ELECTROCHROMIC DEVICES | GENTEX CORP (US) | 2024-02-28 | — | — | EP | claimed |
| US-10459307-B2 | Flame retardancy of electrochromic devices | GENTEX CORPORATION (US) | 2019-10-29 | — | — | US | claimed |
| WO-2017183004-A1 | FLAME RETARDANCY OF ELECTROCHROMIC DEVICES | GENTEX CORPORATION (US) | 2017-10-26 | — | — | WO | claimed |
| US-20170307952-A1 | FLAME RETARDANCY OF ELECTROCHROMIC DEVICES | GENTEX CORPORATION | 2017-10-26 | — | — | US | claimed |
| EP-3446177-B1 | FLAME RETARDANCY OF ELECTROCHROMIC DEVICES | GENTEX CORP (US) | 2024-02-28 | — | — | EP | disclosed |
| US-20210318613-A9 | RADIATION-SENSITIVE RESIN COMPOSITION AND RESIST PATTERN-FORMING METHOD | JSR CORPORATION (JP) | 2021-10-14 | — | — | US | disclosed |
| US-20200393761-A1 | RADIATION-SENSITIVE RESIN COMPOSITION AND RESIST PATTERN-FORMING METHOD | JSR CORPORATION (JP) | 2020-12-17 | — | — | US | disclosed |
| US-10459307-B2 | Flame retardancy of electrochromic devices | GENTEX CORPORATION (US) | 2019-10-29 | — | — | US | disclosed |
| WO-2017183004-A1 | FLAME RETARDANCY OF ELECTROCHROMIC DEVICES | GENTEX CORPORATION (US) | 2017-10-26 | — | — | WO | disclosed |
| US-20170307952-A1 | FLAME RETARDANCY OF ELECTROCHROMIC DEVICES | GENTEX CORPORATION | 2017-10-26 | — | — | US | disclosed |
| US-8106222-B2 | Fluorine-containing ether compound | FUJIFILM CORPORATION (JP) | 2012-01-31 | — | — | US | disclosed |
| US-20090018350-A1 | NOVEL FLUORINE-CONTAINING ETHER COMPOUND | FUJIFILM CORPORATION (JP) | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018350-A1 | NOVEL FLUORINE-CONTAINING ETHER COMPOUND | AFF4, AFF1, AFF2 | THRB 2210/4885TET2 1835/4885MEN1 1829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.